River & Mercantile Asset Management LLP increased its position in Eli Lilly and Co (NYSE:LLY) by 29.0% in the fourth quarter, Holdings Channel reports. The institutional investor owned 85,800 shares of the company’s stock after acquiring an additional 19,300 shares during the period. River & Mercantile Asset Management LLP’s holdings in Eli Lilly and were worth $7,251,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the company. Buckley Wealth Management LLC acquired a new position in shares of Eli Lilly and in the fourth quarter valued at approximately $421,000. NuWave Investment Management LLC acquired a new position in shares of Eli Lilly and in the fourth quarter valued at approximately $1,292,000. Wealthstreet Investment Advisors LLC acquired a new position in shares of Eli Lilly and in the fourth quarter valued at approximately $3,112,000. Gradient Investments LLC acquired a new position in shares of Eli Lilly and in the fourth quarter valued at approximately $103,000. Finally, Girard Partners LTD. increased its position in Eli Lilly and by 19.0% during the fourth quarter. Girard Partners LTD. now owns 8,114 shares of the company’s stock worth $685,000 after purchasing an additional 1,297 shares during the last quarter. 76.20% of the stock is owned by institutional investors and hedge funds.

Several equities analysts recently commented on the stock. BMO Capital Markets set a $73.00 price target on shares of Eli Lilly and and gave the stock a “sell” rating in a research report on Tuesday, October 24th. Berenberg Bank reaffirmed a “buy” rating and set a $98.00 price target on shares of Eli Lilly and in a research report on Thursday, October 26th. Zacks Investment Research lowered shares of Eli Lilly and from a “buy” rating to a “hold” rating in a research report on Monday, October 30th. Credit Suisse Group reaffirmed a “hold” rating on shares of Eli Lilly and in a research report on Wednesday, December 13th. Finally, Leerink Swann upped their price target on shares of Eli Lilly and from $92.00 to $93.00 and gave the stock a “market perform” rating in a research report on Monday, October 23rd. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the company’s stock. Eli Lilly and presently has an average rating of “Hold” and an average price target of $92.02.

Shares of Eli Lilly and Co (LLY) opened at $76.23 on Monday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38. Eli Lilly and Co has a 52 week low of $73.69 and a 52 week high of $89.09. The stock has a market cap of $83,940.00, a P/E ratio of -381.15, a price-to-earnings-growth ratio of 1.39 and a beta of 0.23.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Wednesday, January 31st. The company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.08 by $0.06. Eli Lilly and had a negative net margin of 0.89% and a positive return on equity of 31.44%. The company had revenue of $6.16 billion during the quarter, compared to the consensus estimate of $5.93 billion. During the same period in the previous year, the firm earned $0.95 earnings per share. Eli Lilly and’s revenue for the quarter was up 7.0% on a year-over-year basis. sell-side analysts predict that Eli Lilly and Co will post 4.88 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 9th. Shareholders of record on Thursday, February 15th will be paid a dividend of $0.5625 per share. This is an increase from Eli Lilly and’s previous quarterly dividend of $0.52. This represents a $2.25 annualized dividend and a yield of 2.95%. The ex-dividend date of this dividend is Wednesday, February 14th. Eli Lilly and’s payout ratio is currently -1,040.00%.

In other news, SVP Susan Mahony sold 36,585 shares of the company’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $86.18, for a total value of $3,152,895.30. Following the completion of the transaction, the senior vice president now directly owns 54,885 shares in the company, valued at $4,729,989.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Lilly Endowment Inc sold 200,000 shares of the company’s stock in a transaction on Wednesday, December 13th. The shares were sold at an average price of $88.20, for a total transaction of $17,640,000.00. Following the completion of the transaction, the insider now owns 123,084,104 shares of the company’s stock, valued at $10,856,017,972.80. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 259,610 shares of company stock valued at $22,727,406. 0.20% of the stock is owned by insiders.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://www.watchlistnews.com/river-mercantile-asset-management-llp-has-7-25-million-stake-in-eli-lilly-and-co-lly/1861188.html.

Eli Lilly and Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.